Previous Close | 1.1000 |
Open | 1.1000 |
Bid | 0.0000 |
Ask | 4.8000 |
Strike | 105.00 |
Expire Date | 2024-06-21 |
Day's Range | 1.1000 - 1.1000 |
Contract Range | N/A |
Volume | |
Open Interest | 47 |
ALISO VIEJO, Calif., June 14, 2024--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, today announced that it entered into separate, privately negotiated exchange agreements (the "Exchange Agreements") with certain holders of its 2.75% Convertible Senior Notes due 2027 (the "Existing Convertible Notes"). Pursuant to these Exchange Agreements, the company agreed, subject to customary closing conditions, to repurchase an aggregate of $230 million princi
Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.